The investigators propose a clinical study of irbersartan for the early treatment of severe
sepsis patients with elevated predicted risk of death between. This study will evaluate
whether early administration of the the angiotensin receptor blocker irbersartan provides
significant reduction of 28 days mortality and multi organ failure incidence to patients with
severe sepsis.